Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer

Gastrointestinal Cancer Research

Volumn 4, Issue 4, 2011, Pages 128-134

  Chuong, Michael D ^a   Hayman, Tom J ^a   Patel, Manish R ^a   Russell, Mark S ^a   Malafa, Mokenge P ^a   Hodul, Pamela J ^a   Springett, Gregory M ^a   Choi, Junsung ^a   Shridhar, Ravi ^a   Hoffe, Sarah E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREATICODUODENECTOMY; RADIATION DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 82055196771     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Varadhachary G, et al: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035-1046, 2006
2. Evans DB, et al: Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepatobiliary Pancreat Surg 5(3):242-50, 1998
3. Wayne JD, et al: Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 7(1):34-45, 2002
4. Li D, et al: Pancreatic cancer. Lancet 363(9414):1049-57, 2004
5. Katz M, et al: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-846, 2008
6. Pingpank J, Hoffman J: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastroint Surg 5(2):121-130, 2001
7. Millikan K: Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65(7):618-623, 1999
8. Benassai G, et al: Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital 52:263-270, 2000
9. Sohn TA, Yeo CJ, Cameron JL: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579, 2000
10. Takai S, Satoi S, and Toyokawa K: Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 26:243-249, 2003
11. Kuhlmann KF, Castro SMd, Wesseling JG: Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 40:549-558, 2004
12. Neoptolemos JP, Stocken DD, Dunn JA: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758-768, 2001
13. Kopelson G: Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 9(6):911-915, 1983
14. Pilepich MV, Miller HH: Preoperative irradiation in carcinoma of the pancreas. Cancer 46(9):1945-1949, 1980
15. Burris H, Moore M, Andersen J: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413, 1997
16. Krishnan S, Rana V, Janjan N: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110(1):47-55, 2007
17. Crane C, Abbruzzese J, Evans D: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52(5):1293-1302, 2002
18. Evans D, Rich T, Byrd D: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127(11):1335-1339, 1992
19. Hoffman J, Lipsitz S, Pisansky T: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16(1):317-323, 1998
20. Pipas JM, et al: Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50(5):1317-1322, 2001
21. McGinn CJ, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19(22):4202-4208, 2001
22. Springett GM, Hoffe SE: Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control 15(4):295-307, 2008
23. Assifi MM, et al: Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150(3):466-473, 2011
24. Wilkowski R, et al: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 28(10):1011-1018, 2004
25. McClaine RJ, et al: Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) 12(1):73-79, 2010
26. Wilkowski R, Thoma M, Schauer R: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 28(10):1011-1018, 2004
27. Safran H, Dipetrillo T, Iannitti D: Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol Biol Phys 54(1):137-141, 2002
28. Muler JH, et al: Phase I trial using a time-toevent continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22(2):238-243, 2004
29. Fine R, Fogelman D, GTX chemotherapy for metastatic pancreatic cancer: response survival, and toxicity data [abstract #4371]. Proceedings of the American Society of Clinical Oncology, 2003
30. Fogelman D: The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am 13:711-735, 2004
31. Mantatzis M, et al: Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol 19(7):1809-1816, 2009
32. Hopper K, Kasales C, Eggli K: The impact of 2D versus 3D quantification of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr 20:930-937, 1996
33. Hoe LV, Cutsem EV, Vergote I: Size quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology 202:671-675, 1997
34. Quivey J, et al: Computerized tomography in the quantitative assessment of tumour response. Br J Cancer 41:30-34, 1980
35. Friedman M, et al: How accurate are computed tomographic scans in assessment of changes in tumor size? Am J Med 75:193-198, 1983
36. Feng M, et al: Characterization of pancreatic tumor motion using 4D MRI: surrogates for tumor position should be used with caution. Int J Rad Oncol 2007:69(3, Supp 1):S3-S4
37. Wu QJ, et al: The impact of respiratory motion and treatment technique on stereotactic body radiation therapy for liver cancer. Med Phys 35(4):1440-1451, 2008
38. Luccichenti G, Cademartiri F, Sianesi M: Radiologic assessment of rectosigmoid cancer before and after neoadjuvant radiation therapy: comparison between quantitation techniques. AJR Am J Roentgenol 184:526-530, 2005
39. Apte MV, Wilson JS: Mechanisms of pancreatic fibrosis. Dig Dis 22(3):273-279, 2004
40. Bachem MG, et al: Role of stellate cells in pancreatic fibrogenesis associated with acute and chronic pancreatitis. J Gastroenterol Hepatol 21(Supp 3):S92-S96, 2006
41. Jaster R: Molecular regulation of pancreatic stellate cell function. Mol Cancer 3:S92-26, 2004
42. Jaster R, Emmrich J: Crucial role of fibrogenesis in pancreatic diseases. Best Pract Res Clin Gastroenterol 22(1):17-29, 2008
43. Masamune A, et al: Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol 7(11 Supp):S48-S54, 2009
44. Shimizu K: Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 43(11):823-832, 2008
45. Zhang G, et al: Re-planning for compensatorbased imrt with original compensators. Med Dosimetry, 2010
46. Pingpank JF, et al: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 5(2):121-130, 2001
47. Therasse P, Arbuk S, Eisenhauer E: New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
48. James K, Eisenhauer E, Christian M: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523-528, 1999
49. Hauth E, Stattaus J, Forsting M: [Comparison of unidimensional and bidimensional measurement to assess therapeutic response in the treatment of solid tumors]. Radiologe 47(7):523-628, 2007
50. Sohaib S, et al: CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 73(875):523-1178, 2000
51. Hopper K, et al: Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol 167:851-854, 1996
52. Marten K, et al: Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol 16(4):781-790, 2006
53. Husband J, et al: Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 90(12):2256-2260, 2004
54. Prasad SR, et al: CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 225(2):416-419, 2002